Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients

Schizophrenia Research

Volumn 98, Issue 1-3, 2008, Pages 295-301

  Kale, Anvita ^a   Joshi, Sadhana ^a   Naphade, Nilesh ^b   Sapkale, Swati ^b   Raju, M S V K ^b   Pillai, Anilkumar ^c,d   Nasrallah, Henry ^e   Mahadik, Sahebarao P ^c,d  

^a Bharati Vidyapeeth Deemed University   (India)

^b Bharati Vidyapeeth's Medical College   (India)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Arachidonic acid; Cerebrospinal fluid; Docosahexaenoic acid; Schizophrenia

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; POLYUNSATURATED FATTY ACID;

ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; ERYTHROCYTE; FATTY ACID METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

ADULT; AGE FACTORS; AMBULATORY CARE; ARACHIDONIC ACID; DIET; DOCOSAHEXAENOIC ACIDS; ERYTHROCYTES; ETHNIC GROUPS; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; LIFE STYLE; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEX FACTORS;

EID: 37049002256     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.09.036     Document Type: Article

References (49)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
2. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans E., Horrobin D.F., Bennett C., Ranjekar P.K., and Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 53 (2003) 56-64
3. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., and Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr. Res. 62 (2003) 195-204
4. Assies J., Lieverse R., Vreken P., Wanders R.J.A., Dingemans P.M.J.A., and Linszen D.H. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol. Psychiatry 49 (2001) 510-522
5. Chong S.A., Subramaniam M., and Verma S. Spontaneous parkinsonism in antipsychotic-naive patients with first-episode psychosis. Can. J. Psychiatry 50 7 (2005) 429-431
6. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., and Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukot. Essent. Fat. Acids 69 (2003) 393-399
7. Fenton W.S., Hibbeln J., and Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis of schizophrenia. Biol. Psychiatry 47 (2000) 8-12
8. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., and Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 158 (2001) 2071-2074
9. Giltay E.J., Gooren L.J., Toorians A.W., Katan M.B., and Zock P.L. Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. Am. J. Clin. Nutr. 80 (2004) 1167-1174
10. Glantz L.A., and Lewis D.A. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: regional and diagnostic specificity. Arch. Gen. Psychiatry 54 (1997) 660-669
11. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology Supple. 2 (2003) 17-54
12. Hibbeln J.R., Makino K.K., Martin C.E., Dickerson F., Boronow J., and Fenton W.S. Smoking gender and dietary influence on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol. Psychiatry 53 (2003) 431-441
13. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 30 (1998) 193-208
14. Horrobin D.F., Manku M.S., Hillman H., Iain A., and Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry 30 (1991) 795-805
15. Innis S.M. Dietary (n-3) fatty acids and brain development. J. Nutr. 137 (2007) 855-859
16. Kaddurah-Daouk R., McEvoy J., Baillie R.A., Lee D., Yao J.K., Doraiswamy P.M., and Krishnan K.R.R. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry (2007) 1-12 10.1038/sj.mp.4002000 online 17 April
17. Kay S., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) For Schizophrenia. Schizophr. Bull. 13 (1987) 261-275
18. Keshavan M.S., Anderson S., and Pettegrew J.W. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J. Psychiatr. Res. 28 (1994) 239-265
19. Keshavan M.S., Duggal H.S., Veeragandham G., McLaughlin N.M., Montrose D.M., Haas G.L., and Schooler N.R. Personality dimensions in first-episode psychoses. Am. J. Psychiatry 162 1 (2005) 102-109
20. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., and Mahadik S.P. Reduced erythrocyte membrane essential fatty acids increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 58 (2002) 1-10
21. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., and Tohen M. HGDH Study Group. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 62 4 (2005) 361-370
22. Lim K.O., Tew W., Kushner M.S.W., Chow K., Matsumoto B., and DeLisi L.E. Cortical gray matter volume deficit in patients with first episode schizophrenia. Am. J. Psychiatry 153 (1996) 1548-1553
23. Mahadik S.P., and Evans D. Essential fatty acids in the treatment of Schizophrenia. Drugs Today 33 (1997) 5-17
24. Mahadik S.P., Sitasawad V., and Mulchandani M. Membrane peroxidation and the neuropathology of Schizophrenia. In: Peet M., Glen A.L., and Horrobin D.F. (Eds). Phospholipid Spectrum Disorders in Psychiatry (1999), Marius Press, Lancashire, UK 99-111
25. Mahadik S.P., Evans D., and Lal H. Oxidative stress and the role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia. Prog. NeuroPsychopharmacol. Biol. Psychiatr 25 (2001) 463-493
26. Mahadik S.P., Khan M.M., and Parikh V. Antipsychotic effects on rat brain essential fatty acids in erythrocytes of schizophrenic patients: treatment implications. In: Peet M., Glen I., and Horrobin D.F. (Eds). Phospholipid Spectrum Disorders in Psychiatry and Neurology. 2nd Edition (2003), Marius Press, Carnforth, Lancashire, UK
27. Mahadik S.P., Pillai A., Joshi S., and Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int. Rev. Psychiatry 18 (2006) 119-131
28. Mahadik S.P., and Yao J.K. Phospholipids in schizophrenia. In: Lieberman J.A., Stroup T.S., and Perkins D.O. (Eds). Textbook of Schizophrenia (2006), American Psychiatric Publishing, Washington, DC 117-135
29. Manku M.S., Horrobin D.F., Huang S., and Morse N. Fatty acids in plasma and red cell membranes. Lipids 18 (1983) 906-908
30. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C.G., Richtand N.M., and Stanford K.E. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr. Res. 91 (2007) 37-50
31. Pall H.S., Williams A.C., Blake D.R., and Lunec J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet ii (1987) 596-597
32. In: Peet M., Glen I., and Horrobin D. (Eds). Phospholipid Spectrum Disorders in Psychiatry and Neurology (2003), Marius Press, Carnforth, Lancashire, UK
33. Peet M., and Horrobin D.F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms, in association with the E-E Multicenter Study Group. J. Psychiatr. Res. 36 (2002) 7-18
34. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., Wagh U.V., Debsikdar V.B., and Mahadik S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 121 (2003) 109-122
35. Reddy R.D., Keshvan M.S., and Yao J.K. Reduced red blood cell membrane essential fatty acids in first episode schizophrenia at neuroleptic-naïve baseline. Schizophr. Bull. 30 (2004) 901-911
36. Sartorius N., Jablensky A., and Krten A. Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychol. Med. 16 (1986) 909-928
37. Selemon L.D., Rajkowska G., and Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry 52 (1995) 805-818
38. Simopoulos A.P. Omega-3 fatty acids in health and disease, and growth and development. Aml J. Clin. Nutr. 54 (1991) 438-463
39. Skinner A.O., Mahadik S.P., and Garver D.L. Thiobarbituric acid reactive substances in the cerebrospinal fluid in schizophrenia. Schizophr. Res. 76 (2005) 83-87
40. Stevens J.R. Brief psychosis: do they contribute to the good prognosis and equal prevalence of schizophrenia in developing countries?. Br. J. Psychiatry 151 (1987) 393-396
41. Susser E., Verma V.M., Malhotra S., Conors S., and Amador X.P. Delineation of acute transient psychotic disorders in developing country setting. Br. J. Psychiatry 167 (1995) 216-219
42. Suzuki H., Manabe S., Wada O., and Crawford M.A. Rapid incorporation of docosahexaenoic acid from dietary sources into brain microsomal, synaptosomal and mitochondrial membranes in adult mice. Int. J. Vitam. Nutr. Res. 67 (1997) 272-278
43. Torrey E.F. Similar incidence worldwide of schizophrenia: case not proven. Br. J. Psychiatry 151 (1987) 132-133
44. Torrey E.F., Barci B.M., Webster M.J., Bartko J.J., Meador-Woodruff J.H., and Knable M.B. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol. Psychiatry 57 (2005) 252-260
45. Wainwright P.E., Huang Y.S., Bulman-Fleming B., Dalby D., Mills D.E., Redden P., and McCutcheon D. The effects of dietary n-3/n-6 ratio on brain development in the mouse: a dose response study with long-chain n-3 fatty acids. Lipids 27 (1992) 98-103
46. Yao J.K., Leonard S., and Reddy R.D. Membrane phospholipid abnormalities in Postmortem brains from schizophrenic patients. Schizophr. Res. 42 (2000) 7-17
47. Yao J.K., Reddy R.D., and van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15 (2001) 287-310
48. Yao J.K., Sistilli C.G., and van Kammen D.P. Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia. Prostaglandins, Leukot. Essent. Fat. Acids 69 (2003) 429-436
49. Zipursky R.B., Lambe E.K., Kapur S., and Mikulis D.J. Cerebral gray matter volume deficits in first episode psychosis. Arch. Gen. Psychiatry 55 (1998) 540-546